Daxor Lands Patent for Continuous Remote Blood Volume Monitoring via Wearables
DXR•Daxor Corporation received U.S. Patent No. 12,635,917 B2 for a Remote Blood Volume Monitor using non-invasive optical sensors in wearable devices. It provides real-time total, plasma and red cell volume updates with patient-specific alerts for heart failure, syncope, anemia and polycythemia management without tracer injections.
1. Patent Grant and Scope
Daxor Corporation was awarded U.S. Patent No. 12,635,917 B2, covering innovative systems and methods for ongoing remote monitoring of a patient’s absolute blood volume status after an initial baseline measurement. The granted patent encompasses the integration of subsequent hematocrit monitoring technologies with Daxor’s advanced blood volume analysis algorithms.
2. Wearable Sensor Integration
The patented system leverages non-invasive optical sensors such as photo-plethysmography embedded in wearable devices to deliver continuous updates on total blood volume, plasma volume and red cell volume without repeat tracer injections. Sophisticated algorithms automatically calculate volume deviations and trigger clinical notifications when customized physiological thresholds are crossed.
3. Clinical Applications and Market Potential
Designed for management of heart failure, syncope, anemia and polycythemia, the technology offers patient-specific treatment guidance and early‐warning alerts that can reduce readmissions and improve outcomes. Integration capabilities with other monitors—including blood pressure, pulse, glucose and blood gas devices—position the system for broad adoption across outpatient and home care settings.
